VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Interesting Hugh MacNaught response to the comment.

<< Previous

Bullboard Posts

Next >>

Comment by jopatcloon May 10, 2024 11:16am

49 Views

Post# 36033611

RE:Interesting Hugh MacNaught response to the comment.

now 0.265 I sense good news from Dr.G.Adams the visionary...will silence the biggest FUDSTERS of Ventripoint in years...dear friends! 4.0 FDA,Sales,PP close,Ascend,GEHC.and more parter $$$

jopatclo wrote: Interesting Hugh MacNaught response to the comment from
The Ventripoint team are world class game changers IMO
Gerald S.’s
comment Hugh MacNaught President and CEO at Ventripoint Diagnostics Ltd. 15h Thank you for the kind words. The interest shown towards VMS+ in the first two days is very encouraging. Registration for the workshops is particularly impressive and we look forward to demonstrating the benefits of VMS+ and the ease of integrating it into clinical workflow.
comment on post

Hugh MacNaught• FollowingPresident and CEO at Ventripoint Diagnostics Ltd.
1 day ago

The calm before the storm. The Ventripoint team including distributor partners AngioPro and Cardiologic completed assembly of our booth at the 2024 AEPC conference in Porto. We look forward to meeting the 1600 delegates at this years meeting and hosting workshops providing live demonstrations of VMS+.
More to come!